Focusing our work on infectious and inflammatory dermatology
SkinDermic® is a drug discovery company focused on developing breakthrough and innovative small molecule drugs for the treatment of infectious and inflammatory skin diseases.
SkinDermic® wants to complete multiple Phase-1 (proof of concept) and Phase-2 clinical trials of its First-in-Class Topical treatments for acne and Kaposi’s sarcoma.
SkinDermic is developing novel, safer and highly effective first-in-class drug candidates, internally discovered, for the treatment of acne and Kaposi’s Sarcoma. SkinDermic’s drug pipeline contains innovative new small molecule drugs and a peptide for the treatment of acne and Kaposi’s Sarcoma. SkinDermic’s business strategy is to partner its proprietary drug candidates.